References
- Vardiman JW, Melo JV, Baccarani M, et al. Chronic myelogenous leukemia, BCR-ABL1 positive. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp. 32–37.
- Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of ABL and BCR genes in chronic myelogenous leukemia. Nature 1985;315: 550–554.
- Kantarjian H, Sawyers C, Hochlaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652.
- Cortes J, O’Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:671–684.
- Navarro JT, Feliu E, Grau J, et al. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. Am J Hematol 2007;82:849–851.
- Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003;98:1905–1911.
- Terre C, Eclache V, Rousselor P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004;18:1340–1346.
- Bumm T, Muller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003;101:1941–1949.
- Mozziconacci MJ, Cailleres S, Maurice C, et al. Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case. Leukemia 2003;17: 1901–1902.
- O’Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003;17: 481–487.
- Alimena G, Breccia M, Mancini M, et al. Clonal evolution in Philadelphia chromosome negative cells following successful treatment with imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome. Leukemia 2004;18:361–362.
- Kovitz C, Kantarjian H, Garcia-Manero G, et al. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006;108:2811–2813.